What Happened?
Shares of medical technology company iRhythm Technologies (NASDAQ: IRTC) jumped 3.4% in the afternoon session after the company announced positive results from two studies for its heart monitoring technology.
The data, presented at the Heart Rhythm Society's 2026 annual meeting, came from analyses of patients who had a previous heart procedure and pregnant patients. The studies found that traditional short-term monitors, which are often used for only 48 hours, missed a large number of heart rhythm problems. In contrast, iRhythm's longer, 14-day monitoring period detected these issues.
Specifically, a large portion of arrhythmias were found after 48 hours but within the 14-day window, highlighting the value of extended monitoring for making better clinical decisions.
After the initial pop the shares cooled down to $126.61, up 3.6% from previous close.
Is now the time to buy iRhythm? Access our full analysis report here, it’s free.
What Is The Market Telling Us
iRhythm’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 18% on the news that the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast.
The medical technology firm disclosed that its revenue jumped 26.1% year-over-year to $186.7 million. The company posted a smaller-than-expected adjusted loss of $0.32 per share, which was a significant improvement over analyst forecasts of a $0.51 loss.
Bolstering investor confidence, iRhythm lifted its full-year 2025 revenue guidance to a range between $720 million and $730 million, substantially higher than the prior consensus estimate. The company also announced an improved gross margin and a new strategic partnership to use artificial intelligence for earlier detection of undiagnosed arrhythmias.
iRhythm is down 27.7% since the beginning of the year, and at $126.61 per share, it is trading 33.1% below its 52-week high of $189.25 from January 2026. Despite the year-to-date decline, investors who bought $1,000 worth of iRhythm’s shares 5 years ago would now be looking at an investment worth $1,591.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
